ChemInform Abstract: A NOVEL ADENOSINE AND ARA‐A, DEAMINASE INHIBITOR, (R)‐3‐(2‐DEOXY‐BETA‐D‐ERYTHROPENTO‐FURANOSYL)‐3,6,7,8‐TETRAHYDROIMIDAZO(4,5‐D)(1,3)DIAZEPIN‐8‐OL

Woo, Peter W. K.; Dion, Henry W.; Lange, Siegfried; Dahl, Lawrence F.; Durham, Lois J.

doi:10.1002/chin.197504446

Cited by 4 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pentostatin (2'-deoxycoformycin, dCF) is a potent tight-binding inhibitor of adenosine deaminase (ADA) [1][2][3]. This enyzme catalyzes the deamination of adenoThc authors wish to thank Ms. M .…”

Section: Introductionmentioning

confidence: 99%

Pentostatin (2′-Deoxycoformycin, dCF) in Patients with Low-Grade (B-T-Cell) and Intermediate- and High-Grade (T-Cell) Malignant Lymphomas: Phase II Study of the EORTC Early Clinical Trials Group

et al. 1996

View full text Add to dashboard Cite

Thirty-seven eligible patients with advanced non-Hodgkin’s lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2′-deoxycoformycin, dCF) 4 mg/m² i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1, 0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months’ median duration (range 7–12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin’s disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.

show abstract

Section: Introductionmentioning

confidence: 99%

Pentostatin (2′-Deoxycoformycin, dCF) in Patients with Low-Grade (B-T-Cell) and Intermediate- and High-Grade (T-Cell) Malignant Lymphomas: Phase II Study of the EORTC Early Clinical Trials Group

et al. 1996

View full text Add to dashboard Cite

show abstract

“…A new cytotoxic antibiotic was discovered by testing the culture filtrates for inhibition of tumor growth in vivo or tumor cell growth in vitro by the inhibition of macromolecular synthesis or inhibition of certain specific enzymes such as reverse transcriptase, glyoxalase, adenosine deaminase and tyrosine protein kinase. Woo et al 73 was found deoxycoformycin in S. antibiotics by screening of adenosine deaminase inhibitors. Glyoxalase inhibitor was isolated from S. filipinensis (Frederick et al, 2000).…”

Section: Marine Actinobacteria- a Source For Protease Inhibitormentioning

confidence: 99%

Protease inhibitors as a potential agent against visceral Leishmaniasis: A review to inspire future study

Sreedharan¹,

Rao²

2023

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

“…This analogue was initially isolated in 1974 from the cultured soil organism Streptomyces antibioticus [7] and its development was based on its activity as a tight-binding ADA inhibitor. This analogue was initially isolated in 1974 from the cultured soil organism Streptomyces antibioticus [7] and its development was based on its activity as a tight-binding ADA inhibitor.…”

Section: Purine Analogues In Therapy: Clinical Activity and Mechanismmentioning

confidence: 99%

The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents

King¹

2008

CCTR

View full text Add to dashboard Cite

Purine nucleoside analogues are extensively used in the treatment of malignancies and viral diseases. For example, cladribine and fludarabine are two purine nucleoside analogues that have activity in the treatment of chronic lymphocytic leukemias. These chemotherapeutic agents exert their cytotoxic actions through interactions with intracellular targets. Due to their hydrophilic nature, many purine nucleoside analogues do not readily diffuse across cell membranes at therapeutic concentrations. The presence or absence of mediated transport systems will therefore have an impact on their pharmacological activities.There are two families of nucleoside transporters with members in human (h) cells and tissues: the equilibrative nucleoside transporters (hENTs) and the concentrative nucleoside transporters (hCNTs). These transporter proteins mediate the uptake of both physiologic nucleosides and nucleoside analogue chemotherapeutic agents. It has been documented that permeant specificity, tissue distribution and cellular localization of these transporters contribute to the antineoplastic activity of the purine nucleoside analogues. This article will review current knowledge of the role of nucleoside transport proteins in the cytotoxic actions of purine nucleoside analogues.

show abstract

ChemInform Abstract: A NOVEL ADENOSINE AND ARA‐A, DEAMINASE INHIBITOR, (R)‐3‐(2‐DEOXY‐BETA‐D‐ERYTHROPENTO‐FURANOSYL)‐3,6,7,8‐TETRAHYDROIMIDAZO(4,5‐D)(1,3)DIAZEPIN‐8‐OL

Abstract: Aus Streptomyces antibioticus wird ein starker Adenosin‐ und Ara‐A‐Desaminase‐ Inhibitor der Struktur (I) isoliert und strukturell sichergestellt.

Cited by 4 publications

References 1 publication

Pentostatin (2′-Deoxycoformycin, dCF) in Patients with Low-Grade (B-T-Cell) and Intermediate- and High-Grade (T-Cell) Malignant Lymphomas: Phase II Study of the EORTC Early Clinical Trials Group

Pentostatin (2′-Deoxycoformycin, dCF) in Patients with Low-Grade (B-T-Cell) and Intermediate- and High-Grade (T-Cell) Malignant Lymphomas: Phase II Study of the EORTC Early Clinical Trials Group

Protease inhibitors as a potential agent against visceral Leishmaniasis: A review to inspire future study

The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents

Contact Info

Product

Resources

About